FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4226250394> ?p ?o ?g. }

• W4226250394 abstract "Background Achieving and maintaining viral suppression (VS) in people living with HIV/AIDS on antiretroviral therapy (ART) remains a crucial clinical goal, more so in pregnancy to prevent mother-to-child-transmission (MTCT). There is a need to understand VS kinetics and barriers to achieving it in order to meet the target of eliminating HIV-MTCT by 2030. Methods HIV-infected pregnant women ≥20 weeks of gestation with different durations of Tenofovir/Lamivudine/Efavirenz exposures seeking antenatal care services at four primary health centres in high-density residential areas in Harare, Zimbabwe were enrolled in the University of Zimbabwe Birth Cohort Study. Plasma viral load (VL) was quantified by reverse transcriptase–polymerase chain reaction. Demographic, clinical, socio-economic and HIV- and ART-related factors were tested in multivariable logistic regression analyses as potential predictors for VS and undetectable VL. Results From March 2016 to June 2019, 608 HIV-infected pregnant women were enrolled. 63 (10.4%) were self-reported-ART-naïve; 324 (53.3%) and 221 (36.3%) initiated ART pre- and post-conception, respectively. Time from ART initiation to VS (VL ≤ 1,000 copies/ml) in 95% of the women was 126 days. Overall lack of VS (VL &gt; 1,000 copies/ml) was observed in 133 (21.9%) women being 76.2, 27.4 and 7.7% in self-reported-ART-naïve, post-conception and pre-conception groups, respectively. Undetectable VL (≤ 50 copies/ml) was observed in 371 (61.2%) and low-level viremia (51–1,000 copies/ml) in 102 (16.8%) women. In multivariable models for all participants regardless of ART exposure, being on ART was the strongest predictor for both VS and undetectable VL (odds ratio 95% confidence interval, OR (CI): 8.9(4.2–19.5) and 8.1(3.2–24.4), respectively). For women on ART, duration of ART use &gt;126 days was the strongest predictor with OR (CI): 6.7(3.3–14.0) for VS and 8.5(5.6–13.1) for undetectable VL. Other relevant predictors for favourable virological outcomes were older maternal age, HIV-status disclosure, absence of ART side effects and self-reported depression. Having a spouse/intimate partner on ART predicted a 4 times higher likelihood for VS. Discussion Lack of VS was frequently observed in this Harare cohort of pregnant women, mainly due to new HIV diagnosis, hence not being on ART and suboptimal duration of ART exposure. Since VS for 95% of women needed about 4 months of ART exposure, eliminating HIV-MTCT will require timely screening and commencing women together with their spouses/intimate partners on ART before pregnancy or early after conception. Clinical Trial Registration www.ClinicalTrials.gov , identifier: NCT04087239." @default.
• W4226250394 created "2022-05-05" @default.
• W4226250394 creator A5002897290 @default.
• W4226250394 creator A5003087732 @default.
• W4226250394 creator A5022852839 @default.
• W4226250394 creator A5052976319 @default.
• W4226250394 creator A5054681942 @default.
• W4226250394 creator A5070212543 @default.
• W4226250394 creator A5076485518 @default.
• W4226250394 creator A5085171564 @default.
• W4226250394 creator A5090880249 @default.
• W4226250394 date "2022-04-06" @default.
• W4226250394 modified "2023-09-26" @default.
• W4226250394 title "Predictors and Timing to Viral Suppression in HIV-Infected Pregnant Women in the University of Zimbabwe Birth Cohort Study During the Era of Lifelong Antiretroviral Therapy (Option B+ Treatment Strategy)" @default.
• W4226250394 cites W1984199026 @default.
• W4226250394 cites W1987680111 @default.
• W4226250394 cites W1993963251 @default.
• W4226250394 cites W2025547915 @default.
• W4226250394 cites W2025846323 @default.
• W4226250394 cites W2033419567 @default.
• W4226250394 cites W2036408211 @default.
• W4226250394 cites W2038647399 @default.
• W4226250394 cites W2052723502 @default.
• W4226250394 cites W2060678628 @default.
• W4226250394 cites W2078381938 @default.
• W4226250394 cites W2089044623 @default.
• W4226250394 cites W2090724511 @default.
• W4226250394 cites W2095708680 @default.
• W4226250394 cites W2111280544 @default.
• W4226250394 cites W2129035077 @default.
• W4226250394 cites W2142635246 @default.
• W4226250394 cites W2150410879 @default.
• W4226250394 cites W2163000974 @default.
• W4226250394 cites W2205698009 @default.
• W4226250394 cites W2345117944 @default.
• W4226250394 cites W2520997901 @default.
• W4226250394 cites W2551002634 @default.
• W4226250394 cites W2551459315 @default.
• W4226250394 cites W2767892198 @default.
• W4226250394 cites W2785503570 @default.
• W4226250394 cites W2790900850 @default.
• W4226250394 cites W2794768567 @default.
• W4226250394 cites W2883201855 @default.
• W4226250394 cites W2890937674 @default.
• W4226250394 cites W2932832435 @default.
• W4226250394 cites W2947191973 @default.
• W4226250394 cites W2972616577 @default.
• W4226250394 cites W2974698933 @default.
• W4226250394 cites W2975064121 @default.
• W4226250394 cites W2990676722 @default.
• W4226250394 cites W2994166505 @default.
• W4226250394 cites W2996375835 @default.
• W4226250394 cites W3039771847 @default.
• W4226250394 cites W3090661401 @default.
• W4226250394 cites W3122407795 @default.
• W4226250394 cites W3127028191 @default.
• W4226250394 cites W3135224421 @default.
• W4226250394 cites W3176846803 @default.
• W4226250394 cites W3177482096 @default.
• W4226250394 cites W3195266715 @default.
• W4226250394 cites W3198112944 @default.
• W4226250394 cites W4254821105 @default.
• W4226250394 doi "https://doi.org/10.3389/fviro.2022.838234" @default.
• W4226250394 hasPublicationYear "2022" @default.
• W4226250394 type Work @default.
• W4226250394 citedByCount "2" @default.
• W4226250394 countsByYear W42262503942023 @default.
• W4226250394 crossrefType "journal-article" @default.
• W4226250394 hasAuthorship W4226250394A5002897290 @default.
• W4226250394 hasAuthorship W4226250394A5003087732 @default.
• W4226250394 hasAuthorship W4226250394A5022852839 @default.
• W4226250394 hasAuthorship W4226250394A5052976319 @default.
• W4226250394 hasAuthorship W4226250394A5054681942 @default.
• W4226250394 hasAuthorship W4226250394A5070212543 @default.
• W4226250394 hasAuthorship W4226250394A5076485518 @default.
• W4226250394 hasAuthorship W4226250394A5085171564 @default.
• W4226250394 hasAuthorship W4226250394A5090880249 @default.
• W4226250394 hasBestOaLocation W42262503941 @default.
• W4226250394 hasConcept C119599485 @default.
• W4226250394 hasConcept C126322002 @default.
• W4226250394 hasConcept C127413603 @default.
• W4226250394 hasConcept C131872663 @default.
• W4226250394 hasConcept C142462285 @default.
• W4226250394 hasConcept C151956035 @default.
• W4226250394 hasConcept C201903717 @default.
• W4226250394 hasConcept C203014093 @default.
• W4226250394 hasConcept C2522874641 @default.
• W4226250394 hasConcept C2776185481 @default.
• W4226250394 hasConcept C2777351918 @default.
• W4226250394 hasConcept C2777869810 @default.
• W4226250394 hasConcept C2779234561 @default.
• W4226250394 hasConcept C2780593183 @default.
• W4226250394 hasConcept C2781432083 @default.
• W4226250394 hasConcept C2993143319 @default.
• W4226250394 hasConcept C3013748606 @default.
• W4226250394 hasConcept C54355233 @default.
• W4226250394 hasConcept C71924100 @default.
• W4226250394 hasConcept C72563966 @default.
• W4226250394 hasConcept C761482 @default.
• W4226250394 hasConcept C86803240 @default.

• next